Pencil Biosciences is developing a truly innovative gene editing technology that can have an impact across a range of applications, including new therapeutic options for patients with rare diseases. The technology is small, modular in design, and non-CRISPR in composition.
The Pharmaceutical Licensing Group, in the UK, has been established for 30 years and is the professional association for those active in pharmaceutical and biotechnology business development and licensing.
There are around 200 members in the UK and over a 1000 in affiliated groups in Europe, Canada and Japan. All sectors of the industry are represented including multinationals, medium and small pharmaceutical companies, biotechnology, generic and consumer companies.
The PLG is a not-for-profit organisation and is managed by a committee of licensing and business development executives from member companies. Details of the Committee members and how to contact them can be found by following the Committee link.
The PLG organises meetings within local countries, a bi-annual European meeting and a bi-annual International meeting. Details of all meetings can be found on the Events page and by linking to other PLG sites on the European page.
Physiomics develops mathematical models to predict the effect of therapeutic drugs. With an experienced team of dedicated scientists they work with their clients to answer their R&D questions and de-risk drug development.
Physiomics are a leading oncology consultancy using proprietary state of the art Virtual TumourTM technology and other tools to predict and better understand the effects of cancer treatments.
They work with partners developing cancer drugs to help them save time and money and achieve better outcomes during pre-clinical and clinical development. They are also developing tools to support cancer treatment in real world settings
Pictura Bio’s groundbreaking diagnostic platform was born out of a unique combination of medical and technical expertise in virology, biophysics and microscopy from the company’s co-founders, Dr Nicole Robb and Nicolas Shiaelis.
Poolbeg Pharma plc (AIM: POLB) is committed to the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, with a growing emphasis on rare and orphan diseases. Its model focusses upon developing its exciting clinical assets and commercialising approved and marketed drugs to support the growth of the Company and the development of its robust pipeline of innovative products, thereby driving significant value creation.
Poolbeg is led by an experienced leadership team with a history of delivering significant shareholder value. The team has been strengthened by the appointment of three former members of the Amryt Pharma plc leadership team, with the intention of repeating Amryt's success and generating near term revenues.
Poolbeg's clinical programmes target large addressable markets including cancer immunotherapy-induced CRS, infectious disease, and metabolic conditions such as obesity with the development of an oral GLP-1R agonist. It uses a cost-effective development philosophy to generate high quality human data to support partnering and further development. Its AI-led infectious disease programmes analyse unique data from human challenge trials to identify clinically relevant drug targets and treatments, leading to faster development and greater commercial appeal.
Precision for Medicine, Oncology and Rare Disease is proud to offer the first comprehensive, fully integrated clinical development solution. We are devoted exclusively to oncology and rare disease, and our teams are passionate about improving the lives of these patients. By combining the progressive science of biomarkers and analytics with our excellence in complex clinical trial execution, we help innovators to invest wisely, discover value sooner and optimize the returns from research.
Contact Precision for Medicine, Oncology and Rare Disease via their website
PrecisionLife is built upon a collective ambition to improve our understanding of complex diseases and create better, more personalized therapy options so that we can help patients to live longer, healthier lives.
The PrecisionLife® platform takes a radical new approach to analysis of complex disease biology based on a wide range of patients’ genomic, clinical, and epidemiological data, enabling the discovery of richer and more useful links between patients, disease sub-groups, targets and drugs.
Our powerful patented data analytics and decision support platforms are built on a unique mathematical framework and deep experience in delivering innovative new technologies and products.
Headquartered near Oxford in the UK, we also have offices in the USA, Denmark and Poland.
